



DOCKET NO.: WYNC-0329/AM101205(NP)

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Gary Paul Stack, et al.

Confirmation No.: 1624

Application No.: 10/659,531

Group Art Unit: 4794


Filing Date: September 10, 2003

Examiner: Not Yet Assigned

For: ANTIDEPRESSANT AZAHETEROCYCLYLMETHYL DERIVATIVES OF  
4,5-DIHYDROIMIDAZO[1,4,5-DE][1,4]BENZOXAZINE

DATE OF DEPOSIT: February 5, 2004

I HEREBY CERTIFY THAT THIS PAPER IS BEING  
DEPOSITED WITH THE UNITED STATES POSTAL  
SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID,  
ON THE DATE INDICATED ABOVE AND IS  
ADDRESSED TO THE UNITED STATES PATENT AND  
TRADEMARK OFFICE, P.O. BOX 1450, ALEXANDRIA,  
VA 22313-1450.

  
TYPED NAME: Wendy A. Choi

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).

- ☒ In accordance with § 1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in § 1.491, before the mailing date

of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of request for continued examination under § 1.114, no additional fee is required.


- ☒ Copies of references listed on the attached Form PTO-1449 are enclosed herewith EXCEPT THAT:
- ☒ In view of the voluminous nature of references 3, 5, 7, 9, 10, 14 and 17, and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in duplicate.

Enclosed is a copy of the corresponding PCT/US03/28469 Search Report dated January 15, 2004, which indicates the references considered to be relevant.

There are no listed references which are not in the English language.

Date: February 5, 2004

  
Wendy A. Choi  
Registration No. 36,697

WOODCOCK WASHBURN LLP  
One Liberty Place - 46th Floor  
Philadelphia, PA 19103  
Telephone: (215) 568-3100  
Facsimile: (215) 568-3439

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. WYNC-0329/ AM101205(NP)	Application No. 10/659,531
		Applicant Gary Paul Stack, et al.	
		Filing Date September 10, 2003	Group 1624
		Confirmation No. 4794	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	1	Artigas, F., et al., "Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors," <i>Arch Gen Psychiatry</i> , March 1994, 51, 248-251	
	2	Blier, P., et al., "Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression," <i>J. of Clinical Psychopharmacology</i> , 1995, 15(3), 217-222	
*	3	Bundgaard, (Ed.), Design of Prodrugs, <i>Elsevier</i> , 1985	
	4	Bundgaard, H., "Means to enhance penetration; Prodrugs as a means to improve the delivery of peptide drugs," <i>Advanced Drug Deliver Reviews</i> , 1992, 8, 1-38	
*	5	Bundgaard, <i>J. of Pharmaceutical Sciences</i> , 1988, 7(285 et seq.)	
	6	Cheetham, S.C., et al., "[ <sup>3</sup> H]paroxetine binding in rat frontal cortex strongly correlates with [ <sup>3</sup> H]5-HT uptake: effect of administration of various antidepressant treatments," <i>Neuropharmacol.</i> , 1993, 32(8), 737-743	
*	7	Eliel, E.L., Stereochemistry of Carbon Compounds, <i>McGraw-Hill</i> , NY, 1962	
	8	Hall, M.D., et al., "[ <sup>3</sup> H]8-hydroxy-2-(Di-n-propylamino)tetralin binding to pre- and postsynaptic 5-hydroxytryptamine sites in various regions of the rat brain," <i>J. Neurochem.</i> , 1985, 44, 1685-1696	
*	9	Higuchi, et al. (Eds.), Prodrugs as Novel Drug Delivery Systems, <i>American Chemical Society</i> , 1975	
*	10	Jacques, et al., Enantiomers, Racemates and Resolutions, <i>Wiley Interscience</i> , NY, 1981	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	

\* A copy of these references will not be forwarded to the U.S. Patent and Trademark Office since they are believed to be too voluminous and may be obtainable by the Examiner.

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. WYNC-0329/ AM101205(NP)	Application No. 10/659,531
		Applicant Gary Paul Stack, et al.	
		Filing Date September 10, 2003	Group 1624
		Confirmation No. 4794	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	11	Krogsgaard-Larsen, et al. (Eds.), "Design and Application of Prodrugs," <i>Textbook of Drug Design and Development</i> , 1991, Chap. 5, 113-191	
	12	Lazareno, S., et al., "Pharmacological characterization of acetylcholine-stimulated [ <sup>3</sup> S]-GTPγS binding mediated by human muscarinic m1-m4 receptors: antagonist studies," <i>Br. J. Pharmacol.</i> , 1993, 109, 1120-1127	
	13	Perez, V., et al., "Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment," <i>The Lancet</i> , May 31, 1997, 349, 1594-1597	
*	14	Remington's Pharmaceutical Sciences, 17 <sup>th</sup> Ed., Gennaro, A.R. (Ed.), <i>Mack Publishing Company, Easton, PA</i> , 1985	
	15	Tome, M.B., et al., "Serotonergic autoreceptor blockade in the reduction of antidepressant latency: personality variables and response to paroxetine and pindolol," <i>J. Affect Disord</i> , 1997, 44, 101-109	
	16	Tome, M.B., et al., "Paroxetine and pindolol: a randomized trial of serotonergic autoreceptor blockade in the reduction of antidepressant latency," <i>Int. Clin. Psychopharmacol</i> , 1997, 12, 81-89	
*	17	Widder, et al. (Eds.), <i>Methods in Enzymology</i> , Academic Press, 1985, Vol. 4	
	18	Wilens, S.H., "Tables of Resolving Agents and Optical Resolutions," <i>Univ. of Notre Dame Press, Notre Dame, IN</i> , E.L. Eliel (Ed.), 1972, page 268-298	
	19	Wilens, S.H., et al., "Strategies in optical resolutions," <i>Tetrahedron</i> , 1977, 33, 2725-2736	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	

\* A copy of these references will not be forwarded to the U.S. Patent and Trademark Office since they are believed to be too voluminous and may be obtainable by the Examiner.



**Form PTO-1449 Modified**

List of Patent and Publications  
Cited by Applicant  
(Use several sheets if necessary)

U.S. Department of Commerce  
Patent and Trademark Office

Docket No.  
WYNC-0329/  
AM101205(NP)

Application No.  
10/659,531

Applicant  
Gary Paul Stack, et al.

Filing Date  
September 10,  
2003

Group  
1624

Confirmation No.  
4794

**U. S. PATENT DOCUMENTS**

Examiner Initial		Document No.	Date	Name	Class	Subclass

**FOREIGN PATENT DOCUMENTS**

Examiner Initial		Document No.	Date	Country	Translation	
					YES	NO
**	20	WO 94/01437 A1	01/20/94	PCT	X	

**EXAMINER**

**DATE CONSIDERED**

\*\* Cited in attached PCT/US03/28469 Search Report dated January 15, 2004